Posted inHematology-Oncology news
Enasidenib plus Venetoclax Shows Promising Activity in IDH2‑Mutant Relapsed/Refractory AML — ENAVEN‑AML Phase 1b/2 Results
The ENAVEN‑AML trial reports that enasidenib combined with venetoclax is feasible and active in relapsed/refractory IDH2‑mutant AML, achieving a 62% overall response rate with manageable toxicity but substantial infectious complications in this heavily pretreated population.
